NO20043536L - Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister - Google Patents

Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister

Info

Publication number: NO20043536L
Authority: NO; Norway
Prior art keywords: prostaglandin; fluoro; receptor antagonists; cycloalkanoindoles; substituted
Prior art date: 2002-01-24

Application number

NO20043536A

Other languages

English (en)

Other versions

NO327322B1 (no

Inventor

Zhaoyin Wang

Claudio Sturino

Carl Berthelette

Nicolas Lachance

Lianhai Li

Original Assignee

Merck Frosst Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-24

Filing date

2004-08-24

Publication date

2004-08-24

2004-08-24 Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc

2004-08-24 Publication of NO20043536L publication Critical patent/NO20043536L/no

2009-06-08 Publication of NO327322B1 publication Critical patent/NO327322B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)

NO20043536A 2002-01-24 2004-08-24 Fluorsubstituert forbindelse og farmasoytisk preparat NO327322B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US35138402P	2002-01-24	2002-01-24
PCT/CA2003/000084 WO2003062200A2 (en)	2002-01-24	2003-01-22	Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists

Publications (2)

Publication Number	Publication Date
NO20043536L true NO20043536L (no)	2004-08-24
NO327322B1 NO327322B1 (no)	2009-06-08

Family

ID=27613492

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO20043536A NO327322B1 (no)	2002-01-24	2004-08-24	Fluorsubstituert forbindelse og farmasoytisk preparat
NO20071193A NO20071193L (no)	2002-01-24	2007-03-02	Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister
NO2009013C NO2009013I2 (no)	2002-01-24	2009-06-19	Laropiprant eller et farmasøytisk akseptabelt saltderav

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO20071193A NO20071193L (no)	2002-01-24	2007-03-02	Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister
NO2009013C NO2009013I2 (no)	2002-01-24	2009-06-19	Laropiprant eller et farmasøytisk akseptabelt saltderav

Country Status (39)

Country	Link
US (6)	US20030158246A1 (no)
EP (3)	EP1470107B1 (no)
JP (2)	JP4008885B2 (no)
KR (2)	KR100859230B1 (no)
CN (3)	CN1902176A (no)
AR (1)	AR038136A1 (no)
AT (1)	ATE414690T1 (no)
AU (1)	AU2003202343B2 (no)
BR (1)	BR0307050A (no)
CA (1)	CA2471952C (no)
CY (3)	CY1108841T1 (no)
DE (2)	DE122009000022I1 (no)
DK (2)	DK2045241T3 (no)
DO (1)	DOP2003000566A (no)
EA (1)	EA006134B1 (no)
EC (1)	ECSP045203A (no)
EG (1)	EG24978A (no)
ES (2)	ES2316717T3 (no)
FR (1)	FR09C0010I2 (no)
GE (1)	GEP20074078B (no)
HR (1)	HRP20040665B1 (no)
IL (3)	IL162825A0 (no)
IS (2)	IS2633B (no)
JO (1)	JO2481B1 (no)
LU (1)	LU91534I2 (no)
MX (1)	MXPA04007167A (no)
MY (1)	MY137040A (no)
NL (1)	NL300377I2 (no)
NO (3)	NO327322B1 (no)
NZ (1)	NZ533786A (no)
PE (1)	PE20030982A1 (no)
PL (1)	PL208527B1 (no)
PT (2)	PT1470107E (no)
RS (2)	RS20100338A (no)
SI (2)	SI2045241T1 (no)
TW (1)	TWI259080B (no)
UA (1)	UA75520C2 (no)
WO (1)	WO2003062200A2 (no)
ZA (1)	ZA200404999B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7273883B2 (en) *	2000-09-14	2007-09-25	Allergan, Inc.	Prostaglandin EP4 antagonist
US7217725B2 (en) *	2000-09-14	2007-05-15	Allergan, Inc.	Prostaglandin D2 antagonist
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
AR041089A1 (es) *	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
WO2004104205A2 (en) *	2003-05-16	2004-12-02	Merck & Co., Inc.	Enzymatic preparation of chiral indole esters
WO2004103970A1 (en) *	2003-05-20	2004-12-02	Merck Frosst Canada Ltd.	Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists
US20080153817A1 (en) *	2003-08-07	2008-06-26	Dirk Beher	Treatment for Alzheimer's Disease and Related Conditions
TWI258478B (en)	2003-10-31	2006-07-21	Arena Pharm Inc	Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
KR100808742B1 (ko)	2004-03-11	2008-02-29	액테리온 파마슈티칼 리미티드	테트라하이드로피리도인돌 유도체
TWI344954B (en) *	2004-04-02	2011-07-11	Merck Sharp & Dohme	Asymmetric hydrogenation process
GT200500284A (es) *	2004-10-15	2006-03-27	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2
WO2006052798A2 (en) *	2004-11-08	2006-05-18	Merck & Co., Inc.	Method of treating pathological blushing
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
JPWO2006068162A1 (ja) *	2004-12-24	2008-06-12	塩野義製薬株式会社	慢性閉塞性肺疾患の治療剤
AU2005320964B2 (en) *	2004-12-27	2011-12-15	Actelion Pharmaceuticals Ltd.	2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists
CA2598273A1 (en) *	2005-02-17	2006-08-24	Merck & Co., Inc.	Method of treating atherosclerosis, dyslipidemias and related conditions
EP1874301A4 (en) *	2005-04-13	2009-05-06	Merck & Co Inc	Niacin receptor agonists, compositions containing such compounds and treatment methods
EP1916245B1 (en)	2005-07-22	2011-10-26	Shionogi & Co., Ltd.	Indole derivative having pgd2 receptor antagonist activity
WO2007010965A1 (ja)	2005-07-22	2007-01-25	Shionogi & Co., Ltd.	Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
JP5147401B2 (ja)	2005-09-06	2013-02-20	塩野義製薬株式会社	Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
ES2618352T3 (es)	2006-06-16	2017-06-21	The Trustees Of The University Of Pennsylvania	Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética
NZ574705A (en)	2006-08-07	2011-12-22	Actelion Pharmaceuticals Ltd	(3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
WO2008097535A2 (en) *	2007-02-08	2008-08-14	Merck & Co., Inc.	Method of treating atherosclerosis, dyslipidemias and related conditions
US20090076117A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched laropiprant
US8501959B2 (en)	2008-06-24	2013-08-06	Panmira Pharmaceuticals, Llc	Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
US8507473B2 (en)	2008-09-11	2013-08-13	Arena Pharmaceuticals, Inc.	3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
EP2346866B1 (en)	2008-09-25	2013-11-27	Merck Canada Inc.	Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
GB2463788B (en) *	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
GB2465062B (en)	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US9180114B2 (en) *	2008-11-26	2015-11-10	President And Fellows Of Harvard College	Neurodegenerative diseases and methods of modeling
US8882678B2 (en)	2009-03-13	2014-11-11	Atrium Medical Corporation	Pleural drainage system and method of use
EP2558447B1 (en)	2010-03-22	2014-09-17	Actelion Pharmaceuticals Ltd.	3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX338516B (es)	2011-04-14	2016-04-20	Actelion Pharmaceuticals Ltd	Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina.
JP5841361B2 (ja) *	2011-06-29	2016-01-13	壽製薬株式会社	三環性化合物及びそれを含有する医薬組成物
AR088377A1 (es) *	2011-10-20	2014-05-28	Siena Biotech Spa	Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102659664B (zh) *	2012-03-28	2015-01-21	中国计量学院	合成分离拉洛皮兰及其类似物的方法
FR3000399B1 (fr) *	2012-12-31	2015-03-27	Galderma Res & Dev	Utilisation topique du laropiprant pour le traitement de la rosacee
FR3000395A1 (fr) *	2012-12-31	2014-07-04	Galderma Res & Dev	Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee
KR101864060B1 (ko)	2014-03-17	2018-06-01	이도르시아 파마슈티컬스 리미티드	아자인돌 아세트산 유도체 및 프로스타글란딘 ｄ2 수용체 조절제로서의 그의 용도
AU2015233046A1 (en)	2014-03-18	2016-11-03	Idorsia Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
JP6770522B2 (ja)	2015-02-13	2020-10-14	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
KR20180053345A (ko)	2015-09-15	2018-05-21	이도르시아 파마슈티컬스 리미티드	결정질 형태
KR102465211B1 (ko)	2018-03-19	2022-11-10	미쯔이가가꾸가부시끼가이샤	표시 소자용 밀봉재 및 그의 경화물, 유기 el 소자용 프레임 밀봉재, 그리고 유기 el 소자용 면 밀봉재

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3535326A (en) *	1967-03-06	1970-10-20	Sumitomo Chemical Co	Certain tetrahydro carboline derivatives
BE787444A (fr) *	1971-08-13	1973-02-12	Hoffmann La Roche	Composes polycycliques
US4009181A (en) *	1973-01-22	1977-02-22	Hoffmann-La Roche Inc.	Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) *	1973-10-01	1977-11-08	American Home Products Corporation	Carbazole acetic acid derivatives
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
DE3768097D1 (de) *	1986-01-23	1991-04-04	Merck Frosst Canada Inc	Tetrahydrocarbazol-1-alkansaeuren.
US5021447A (en) *	1986-01-23	1991-06-04	Merck Frosst Canada, Inc.	Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4808608A (en)	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US4940719A (en) *	1986-03-27	1990-07-10	Merck Frosst Canada, Inc.	Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) *	1987-07-21	1988-10-04	Merck & Co., Inc.	Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
US5221678A (en)	1990-07-26	1993-06-22	Merck Frosst Canada, Inc.	(quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
GB9101375D0 (en)	1991-01-22	1991-03-06	Erba Carlo Spa	N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
AU693143B2 (en)	1993-12-06	1998-06-25	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
US5510332A (en)	1994-07-07	1996-04-23	Texas Biotechnology Corporation	Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
WO1996001644A1 (en)	1994-07-11	1996-01-25	Athena Neurosciences, Inc.	Inhibitors of leukocyte adhesion
US5811391A (en)	1994-08-25	1998-09-22	Cytel Corporation	Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en)	1994-12-24	1996-01-31	Zeneca Ltd	Chemical compounds
US6306840B1 (en)	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
WO1996031206A2 (en)	1995-04-07	1996-10-10	Warner-Lambert Company	Flavones and coumarins as agents for the treatment of atherosclerosis
WO1996040781A1 (en)	1995-06-07	1996-12-19	Tanabe Seiyaku Co., Ltd.	CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
HUP9802678A3 (en)	1995-06-21	1999-12-28	Shionogi & Co	Bicyclic amino derivatives and pgd2 antagonist containing the same
US6034057A (en)	1995-07-06	2000-03-07	Zeneca Limited	Peptide inhibitors of fibronectine
US6248713B1 (en)	1995-07-11	2001-06-19	Biogen, Inc.	Cell adhesion inhibitors
JP3215441B2 (ja)	1996-12-13	2001-10-09	塩野義製薬株式会社	ベンゾチオフェンカルボン酸アミド誘導体およびそれを含有するｐｇｄ２拮抗剤
WO1999062555A1 (en)	1998-06-03	1999-12-09	Shionogi & Co., Ltd.	Remedies for itching containing pgd2 antagonists
US20010047027A1 (en)	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
US6410583B1 (en) *	2000-07-25	2002-06-25	Merck Frosst Canada & Co.	Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives

2003
- 2003-01-14 AR ARP030100093A patent/AR038136A1/es active IP Right Grant
- 2003-01-16 JO JO20032A patent/JO2481B1/en active
- 2003-01-16 MY MYPI20030139A patent/MY137040A/en unknown
- 2003-01-21 PE PE2003000068A patent/PE20030982A1/es not_active Application Discontinuation
- 2003-01-21 US US10/348,403 patent/US20030158246A1/en not_active Abandoned
- 2003-01-22 ES ES03700740T patent/ES2316717T3/es not_active Expired - Lifetime
- 2003-01-22 DE DE122009000022C patent/DE122009000022I1/de active Pending
- 2003-01-22 CA CA002471952A patent/CA2471952C/en not_active Expired - Fee Related
- 2003-01-22 NZ NZ533786A patent/NZ533786A/en not_active IP Right Cessation
- 2003-01-22 PT PT03700740T patent/PT1470107E/pt unknown
- 2003-01-22 EP EP03700740A patent/EP1470107B1/en not_active Expired - Lifetime
- 2003-01-22 CN CNA038026759A patent/CN1902176A/zh active Pending
- 2003-01-22 KR KR1020047011489A patent/KR100859230B1/ko not_active Expired - Fee Related
- 2003-01-22 ES ES08105552T patent/ES2391747T3/es not_active Expired - Lifetime
- 2003-01-22 CN CN201010164113A patent/CN101851191A/zh active Pending
- 2003-01-22 HR HR20040665 patent/HRP20040665B1/xx not_active IP Right Cessation
- 2003-01-22 EA EA200400971A patent/EA006134B1/ru not_active IP Right Cessation
- 2003-01-22 KR KR1020077010548A patent/KR20070056166A/ko not_active Withdrawn
- 2003-01-22 EP EP10182463.9A patent/EP2295409B1/en not_active Expired - Lifetime
- 2003-01-22 DK DK08105552.7T patent/DK2045241T3/da active
- 2003-01-22 SI SI200332197T patent/SI2045241T1/sl unknown
- 2003-01-22 RS RSP-2010/0338A patent/RS20100338A/sr unknown
- 2003-01-22 DE DE60324767T patent/DE60324767D1/de not_active Expired - Lifetime
- 2003-01-22 AU AU2003202343A patent/AU2003202343B2/en not_active Ceased
- 2003-01-22 US US10/502,380 patent/US7317036B2/en not_active Expired - Lifetime
- 2003-01-22 PT PT08105552T patent/PT2045241E/pt unknown
- 2003-01-22 CN CNA2007101263979A patent/CN101092388A/zh active Pending
- 2003-01-22 AT AT03700740T patent/ATE414690T1/de active
- 2003-01-22 SI SI200331470T patent/SI1470107T1/sl unknown
- 2003-01-22 DK DK03700740T patent/DK1470107T3/da active
- 2003-01-22 RS YU62404A patent/RS51672B/sr unknown
- 2003-01-22 EP EP08105552A patent/EP2045241B1/en not_active Expired - Lifetime
- 2003-01-22 IL IL16282503A patent/IL162825A0/xx unknown
- 2003-01-22 UA UA20040807066A patent/UA75520C2/uk unknown
- 2003-01-22 GE GE5688A patent/GEP20074078B/en unknown
- 2003-01-22 BR BR0307050-6A patent/BR0307050A/pt not_active IP Right Cessation
- 2003-01-22 WO PCT/CA2003/000084 patent/WO2003062200A2/en not_active Ceased
- 2003-01-22 PL PL370427A patent/PL208527B1/pl not_active IP Right Cessation
- 2003-01-22 JP JP2003562082A patent/JP4008885B2/ja not_active Expired - Fee Related
- 2003-01-22 MX MXPA04007167A patent/MXPA04007167A/es active IP Right Grant
- 2003-01-23 TW TW092101476A patent/TWI259080B/zh not_active IP Right Cessation
- 2003-01-24 DO DO2003000566A patent/DOP2003000566A/es unknown
- 2003-01-25 EG EG2003010067A patent/EG24978A/xx active
2004
- 2004-06-21 IS IS7329A patent/IS2633B/is unknown
- 2004-06-24 ZA ZA200404999A patent/ZA200404999B/en unknown
- 2004-07-01 IL IL162825A patent/IL162825A/en active IP Right Grant
- 2004-07-22 EC EC2004005203A patent/ECSP045203A/es unknown
- 2004-08-24 NO NO20043536A patent/NO327322B1/no not_active IP Right Cessation
2005
- 2005-11-04 US US11/266,919 patent/US20060069148A1/en not_active Abandoned
2007
- 2007-02-26 JP JP2007045469A patent/JP2007186521A/ja active Pending
- 2007-03-02 NO NO20071193A patent/NO20071193L/no not_active Application Discontinuation
- 2007-07-23 US US11/880,557 patent/US7618994B2/en not_active Expired - Lifetime
2008
- 2008-01-17 IL IL188844A patent/IL188844A0/en unknown
2009
- 2009-02-09 CY CY20091100147T patent/CY1108841T1/el unknown
- 2009-02-20 NL NL300377C patent/NL300377I2/nl unknown
- 2009-02-27 LU LU91534C patent/LU91534I2/fr unknown
- 2009-03-12 FR FR09C0010C patent/FR09C0010I2/fr active Active
- 2009-03-31 CY CY200900004C patent/CY2009004I2/el unknown
- 2009-06-19 NO NO2009013C patent/NO2009013I2/no unknown
- 2009-09-30 US US12/570,859 patent/US20100081696A1/en not_active Abandoned
2010
- 2010-03-01 IS IS8887A patent/IS8887A/is unknown
2012
- 2012-01-19 US US13/353,974 patent/US20120115921A1/en not_active Abandoned
- 2012-09-17 CY CY20121100844T patent/CY1113330T1/el unknown

Also Published As

Publication number	Publication date
RS62404A (sr)	2006-12-15
US20030158246A1 (en)	2003-08-21
US20050124680A1 (en)	2005-06-09
AU2003202343B2 (en)	2007-07-12
CY2009004I1 (el)	2009-11-04
IL162825A0 (en)	2005-11-20
US20120115921A1 (en)	2012-05-10
NO327322B1 (no)	2009-06-08
ECSP045203A (es)	2004-09-28
KR20040075109A (ko)	2004-08-26
BR0307050A (pt)	2004-10-26
JP4008885B2 (ja)	2007-11-14
IS8887A (is)	2010-03-01
CA2471952A1 (en)	2003-07-31
JP2007186521A (ja)	2007-07-26
EP2295409B1 (en)	2014-07-02
CN101092388A (zh)	2007-12-26
US20080033028A1 (en)	2008-02-07
LU91534I2 (fr)	2009-04-27
NO2009013I1 (no)	2009-06-29
PE20030982A1 (es)	2003-11-19
NO2009013I2 (no)	2012-08-27
IL162825A (en)	2010-12-30
WO2003062200A3 (en)	2003-12-04
IL188844A0 (en)	2009-02-11
ES2316717T3 (es)	2009-04-16
EA200400971A1 (ru)	2004-12-30
KR20070056166A (ko)	2007-05-31
CN1902176A (zh)	2007-01-24
TWI259080B (en)	2006-08-01
IS2633B (is)	2010-06-15
CY1108841T1 (el)	2011-04-06
EP2295409A1 (en)	2011-03-16
FR09C0010I2 (no)	2009-12-18
EG24978A (en)	2011-04-03
KR100859230B1 (ko)	2008-09-18
NZ533786A (en)	2006-11-30
EP2045241A1 (en)	2009-04-08
IS7329A (is)	2004-06-21
EP2045241B1 (en)	2012-07-04
PT1470107E (pt)	2009-01-30
DK1470107T3 (da)	2009-03-09
MXPA04007167A (es)	2004-10-29
HRP20040665B1 (en)	2012-11-30
AU2003202343C1 (en)	2003-09-02
SI1470107T1 (sl)	2009-04-30
US20060069148A1 (en)	2006-03-30
DK2045241T3 (da)	2012-10-15
UA75520C2 (en)	2006-04-17
EA006134B1 (ru)	2005-10-27
SI2045241T1 (sl)	2012-11-30
US20100081696A1 (en)	2010-04-01
NO20071193L (no)	2004-08-24
ZA200404999B (en)	2006-05-31
DOP2003000566A (es)	2003-09-15
JP2005518413A (ja)	2005-06-23
FR09C0010I1 (no)	2009-04-17
CA2471952C (en)	2008-04-01
RS51672B (sr)	2011-10-31
AR038136A1 (es)	2004-12-29
PT2045241E (pt)	2012-09-26
PL370427A1 (en)	2005-05-30
CY2009004I2 (el)	2009-11-04
CY1113330T1 (el)	2016-06-22
PL208527B1 (pl)	2011-05-31
NL300377I1 (nl)	2009-05-06
JO2481B1 (en)	2009-01-20
RS20100338A (sr)	2011-06-30
ATE414690T1 (de)	2008-12-15
TW200302090A (en)	2003-08-01
US7317036B2 (en)	2008-01-08
US7618994B2 (en)	2009-11-17
GEP20074078B (en)	2007-03-26
CN101851191A (zh)	2010-10-06
NL300377I2 (nl)	2009-08-03
DE122009000022I1 (de)	2009-08-06
MY137040A (en)	2008-12-31
WO2003062200A2 (en)	2003-07-31
DE60324767D1 (de)	2009-01-02
EP1470107A2 (en)	2004-10-27
HRP20040665A2 (en)	2005-04-30
ES2391747T3 (es)	2012-11-29
EP1470107B1 (en)	2008-11-19

Publication	Publication Date	Title
NO20043536L (no)	2004-08-24	Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister
DK1558615T3 (da)	2007-12-03	Purin-forbindelser og deres anvendelse som cannabinoid receptor ligander
DK1723116T3 (da)	2009-02-02	Tetrahydroquinolinoner og deres anvendelse som antagonister for metabotropiske glutamatreceptorer
NO20055135D0 (no)	2005-11-02	Fenylguinoliner og deres anvendelse som ostrogenreseptormodulatorer
NO20030471D0 (no)	2003-01-30	Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
DK1761529T3 (da)	2008-03-25	Pyrrolopyridinderivater og deres anvendelse som CRTh2-antagonister
DK1539712T3 (da)	2008-03-17	Pyrimidinderivater og deres anvendelse som CB2-modulatorer
DK1480955T3 (da)	2007-10-29	O-cyclopropyl-carboxanilider og deres anvendelse som fungicider
DE60325025D1 (de)	2009-01-15	Modulatoren des vanilloidrezeptors
DK1448535T3 (da)	2011-05-23	Benzamid og heteroarylamid som P2X7-receptor antagonister
DK1501815T3 (da)	2007-04-02	Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer
DK1718641T3 (da)	2007-12-17	Benzimidazolderivat og dets anvendelse som All-receptorantagonist
NO20032699L (no)	2003-06-13	Nye sulfonamider og deres anvendelse som endothelinreseptorantagonister
NO20034324D0 (no)	2003-09-26	Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor
DK1581518T3 (da)	2011-06-06	Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister
NO20041008L (no)	2004-03-10	Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
NO20051042L (no)	2005-03-31	Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
DK1170288T3 (da)	2004-11-29	Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister
DK1578727T3 (da)	2008-08-04	Tetrahydroquinolin-derivater og deres anvendelse som FSH-receptor-modulatorer
NO20044373L (no)	2004-10-14	Azetidinderivater som CCR-3-reseptorantagonister
DE60327447D1 (de)	2009-06-10	Pflaster
NO20043799L (no)	2004-09-10	2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister
DK1558259T3 (da)	2011-07-11	Ureaderivater som IL-8 -receptorantagonister
DK1492796T3 (da)	2007-12-03	Substituerede aminoisoxazolinderivater og deres anvendelse som antidepressive midler
NO20053598L (no)	2005-09-20	Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister.

Legal Events

Date	Code	Title	Description
2012-08-27	SPCG	Granted supplementary protection certificate	Spc suppl protection certif: 2009013 Filing date: 20090619 Extension date: 20230703
2015-08-24	MM1K	Lapsed by not paying the annual fees
2023-07-10	SPCX	Expiry of an spc	Spc suppl protection certif: 2009013 Effective date: 20230705

Date

Code

Title

Description

2012-08-27

SPCG

Granted supplementary protection certificate

Spc suppl protection certif: 2009013

Filing date: 20090619

Extension date: 20230703

2015-08-24

MM1K

Lapsed by not paying the annual fees

2023-07-10

SPCX

Expiry of an spc